Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genetic Familial Hypercholesterolemia Prevalent in Premature CVD

By LabMedica International staff writers
Posted on 12 Jun 2019
Premature coronary artery disease (CAD) is a major cause of mortality and morbidity. More...
Increased low-density lipoprotein-cholesterol (LDL-C) level is a major risk factor for CAD and thus the main target for its prevention.

Familial Hypercholesterolemia (FH) is a genetic inherited disorder characterized by high LDL-C, and subsequent premature CAD development. Early drug treatment with lipid-lowering medications in FH prevents cardiovascular disease onset. The FH prevalence in the Northern European general population is 0.3%, and it is estimated that it explains 20% of premature CAD cases in individuals with familial clustering.

Medical scientists and their associates at the Sahlgrenska University Hospital (Gothenburg, Sweden) identified 66 patients out of 218 (30%) who underwent coronary angiography with suspected premature acute coronary syndrome, who agreed to undergo genetic screening to identify FH causing mutations. Of these, 49 had a confirmed diagnosis of premature CAD after coronary angiography.

Blood samples were collected and serum lipid levels (including total cholesterol, LDL-C, HDL-C and triglycerides) were determined by routine techniques at the admittance. LDL-C levels before treatment were available in 91% individuals (60 out of 66). LDL-C levels for those six patients in whom the pretreatment values were not available were quantified based on the estimated effect of the different statins.

DNA was isolated from whole blood and targeted sequenced using SEQPRO LIPO IS and the three main FH-related genes were sequenced, namely LDLR, APOB and PCSK9. For patients negative for FH-causing mutations, the LDL-raising SNP score was calculated using weighted sums for six selected SNPs. Genotyping for the six SNPs was performed in duplicate by TaqMan 5ʹ-nuclease assays with a concordance between duplicates and a success rate of 100%.

The investigators found a causative mutation in three individuals out of 66 screened (prevalence 4.5%). Compared to an estimated frequency of genetic FH of 0.3% in the general Northern European population, this would account for a 15-fold enrichment. When considering individuals with confirmed CAD after coronary angiography, the FH mutation prevalence was 6.1% (3/49). After excluding individuals with classical risk factors for CAD other than hypercholesterolemia, the FH mutation prevalence raised to 15.8% (3/19). Untreated LDL-cholesterol levels in individuals with FH mutation were 2-fold higher than in those without mutation (7.17 ± 2.67 versus 3.55 ± 1.17 mmol/L).

The authors concluded that they had found a high prevalence of FH mutations in young subjects who underwent coronary angiography. Their results support the importance to implement an FH genetic screening program for patients at high risk for CAD and for their families, even independently of untreated LDL-C values. They also found that their cohort was generally undertreated in terms of LDL-C lowering targets. The study was published on May 24, 2019, in the journal The Application of Clinical Genetics.

Related Links:
Sahlgrenska University Hospital


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PSA Assay
CanAg PSA EIA
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.